Related Experiment Video

Updated: Oct 19, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.7K

Current management and prognosis of patients with recurrent myocardial infarction

Leonardo De Luca1, Luca Paolucci2, Annunziata Nusca2

  • 1Department of Cardiosciences, Division of Cardiology, A. O. San Camillo-Forlanini, 00152 Rome, Italy.

Reviews in Cardiovascular Medicine
|September 26, 2021
PubMed

Insights

Recurrent myocardial infarction (re-MI) is a common risk after acute coronary syndrome (ACS), increasing mortality. This overview covers re-MI epidemiology, prognosis, and current prevention strategies for better patient outcomes.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Epidemiology

Background:

  • Recurrent myocardial infarction (re-MI) frequently occurs after acute coronary syndrome (ACS), particularly within the first year.
  • Patients experiencing re-MI face elevated risks of all-cause cardiovascular events and mortality.

Purpose of the Study:

  • To provide an overview of the epidemiological and prognostic data for ACS patients who experience re-MI.
  • To summarize current treatment and preventive options for re-MI.

Main Methods:

  • Review of epidemiological studies on re-MI incidence and risk factors.
  • Analysis of prognostic data concerning cardiovascular events and mortality in re-MI patients.
  • Synthesis of current guidelines and literature on re-MI management and prevention.

Main Results:

  • Re-MI is a significant concern post-ACS, with substantial associated risks.
  • Key preventive measures include complete coronary revascularization, dual antiplatelet therapy, and secondary prevention.
  • Despite established strategies, definitions and management of re-MI remain subjects of ongoing discussion.

Conclusions:

  • Effective management of re-MI is crucial for improving outcomes in ACS survivors.
  • Further dedicated research is needed to address existing controversies in re-MI definition and treatment.
  • Comprehensive secondary prevention strategies are essential for mitigating re-MI risk.

Keywords:
Acute coronary syndromeDual antiplatelet therapyPercutaneous coronary interventionRecurrent myocardial infarctionSecondary prevention

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K
Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.2K

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
58
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
53
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
31
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
67
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
52
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
51